X连锁低磷性佝偻病肾功能评估的挑战:公式高估与FGF23效应
该单中心回顾性研究纳入20例成人XLH患者,比较CKD-EPIcreat和CKD-EPIcyst公式估算的eGFR与实测mGFR。结果显示eGFR显著高估mGFR,CKD-EPIcreat偏差更大且准确性更低;5例患者使用burosumab后mGFR下降,提示FGF23可能影响GFR。
要点
- XLH患者中eGFR公式显著高估mGFR,CKD-EPIcreat准确性仅25%。
- 疑似CKD时建议每年测量胱抑素C以评估肾功能。
- burosumab治疗患者需考虑FGF23对GFR的潜在影响。
核心结论
- eGFR公式在XLH患者中高估GFR,增加CKD误分类风险。
- 疑似CKD时推荐每年测量胱抑素C。
- burosumab治疗患者应考虑FGF23对GFR的影响。
研究设计与样本
- 单中心回顾性研究纳入20例成人XLH患者(17例女性,中位年龄35岁)。
- 比较CKD-EPIcreat和CKD-EPIcyst公式eGFR与实测mGFR的偏差、精确度和准确性。
- 亚组分析burosumab起始后mGFR变化,并在14例纤维性骨发育不良儿科患者中分析FGF23与eGFR相关性。
主要发现
- 中位mGFR为90(85-107)mL/min/1.73 m²,显著低于CKD-EPIcreat的125(114-121)和CKD-EPIcyst的103(118)(P < .0001和P = .01)。
- CKD-EPIcreat偏差为-22(-29至-13),显著大于CKD-EPIcyst的-13(-19至-4),准确性分别为25%和93%。
- 5例XLH患者burosumab起始后mGFR从98降至84 mL/min/1.73 m²。
- 14例纤维性骨发育不良患者中FGF23与eGFR中度相关(R = 0.62,P = .02)。
关键数值与推荐
- 疑似CKD时推荐每年测量胱抑素C。
- burosumab治疗患者需考虑FGF23对GFR的影响。
临床怎么用
- XLH患者评估肾功能时不应仅依赖肌酐-based eGFR,应结合胱抑素C。
- 对burosumab治疗患者需关注GFR变化,警惕FGF23相关高滤过影响。
局限性
- 单中心回顾性研究,样本量小(20例成人XLH)。
- burosumab亚组仅5例,FGF23/GFR关系在纤维性骨发育不良儿科队列中分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In X-linked hypophosphatemia (XLH), phosphate and vitamin D analogs increase the risk of nephrocalcinosis and renal impairment. Kidney function assessment is challenging, as creatinine-based estimated glomerular filtration rate (eGFR) may overestimate GFR because of reduced muscle mass. Cystatin C alternatively may be used. Moreover, fibroblast growth factor 23 (FGF23) has been suggested to potentially impact GFR, leading to hyperfiltration and complicating kidney function assessment. METHODS: We conducted a single-center retrospective study on adults with XLH to compare eGFR formulas (CKD-EPIcreat, CKD-EPIcyst) with true measured GFR (mGFR). Bias, precision, and accuracy were calculated. In a subgroup, mGFR changes after burosumab initiation were assessed. Finally, we analyzed the FGF23/GFR relationship in a pediatric cohort in whom FGF23 was also hypersecreted (fibrous dysplasia) to support our hypothesis that FGF23 leads to hyperfiltration. RESULTS: We included 20 patients (17 females, median age 35 years). None had nephrocalcinosis or hypercalciuria, but 8 had secondary hyperparathyroidism. Median mGFR was 90 (85-107) mL/min/1.73 m², significantly lower than CKD-EPIcreat (125 [114-121]) and CKD-EPIcyst (103 [118]) (respectively P < .0001 and P = .01). Bias was significantly greater with CKD-EPIcreat (-22 [-29 to -13]) than CKD-EPIcyst (-13 [-19 to -4]), with lower accuracy (25% vs 93%). In 5 patients with XLH, mGFR decreased from 98 to 84 mL/min/1.73 m² after burosumab introduction. FGF23 moderately correlated with eGFR in 14 fibrous dysplasia patients (R = 0.62, P = .02). CONCLUSION: eGFR overestimates GFR in XLH, increasing CKD misclassification risk. Annual cystatin C measurement is recommended if CKD is suspected. FGF23 impact on GFR should also be considered in burosumab-treated patients.
引用
- Lemoine S, De Mul A, Perge K, et al. Challenges in Estimating Renal Function in X-linked Hypophosphatemia Because of Formula Overestimation and FGF23 Effects. J Clin Endocrinol Metab. 2026. PMID: 40852855. doi:10.1210/clinem/dgaf459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。